Background: In vitro and clinical studies using parenteral fosfomycin have suggested the possibility of using this drug against infections caused by MDR microorganisms. The aim of this study was to describe a case series of patients treated with fosfomycin who had severe infections caused by pan-drug-resistant Gram-negative bacteria.
Introduction
Treatment of MDR microorganisms is difficult.
1 MDR Gram-negative microorganisms are treated with either colistin or polymyxin B alone or in combination. 2 However, resistance to these has increased. 1 Fosfomycin is a low-molecular-weight compound unrelated to other antimicrobials and interferes in cell wall synthesis after binding to UDP-GlcNAc-3-O-enolpyruvyltransferase (MurA), responsible for peptidoglycan biosynthesis. 3 In vitro studies showed susceptibility of MDR Gram-negative bacteria to fosfomycin and synergism between fosfomycin and other antimicrobials. 4 Oral fosfomycin is used to treat uncomplicated urinary infections. 5 A few heterogeneous or retrospective studies have suggested the possibility of using the parenteral form against MDR microorganisms.
5-8
Prospective studies are scarce. 9 The aim of this study was to describe a series of cases of severe infections caused by MDR Gram-negative bacteria, treated with intravenous fosfomycin.
Methods

Setting and patients
We studied a prospective series of cases of healthcare-associated infections caused by b-lactam-and colistin-resistant Gram-negative bacteria at two tertiary-care teaching hospitals, treated with fosfomycin during the period 2013-16. Patients were excluded if they had allergy to fosfomycin, were ,18 years old, were pregnant or lactating, were unable to consent or undergoing dialysis, had Acinetobacter infections, had non-bacteraemic urinary infections, were at high risk of death within 48 h (determined by the attending physician) or required treatment for .30 days.
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Protocol
The study was approved by the Ethics Committees of Hospital das Clínicas and Hospital Geral de Fortaleza for compassionate use of fosfomycin; the microorganism was not susceptible to any other antimicrobial. Thus, candidate patients for this compassionate use were those with severe infections with no antimicrobial therapy option. Informed consent was obtained from all patients. Patients received intravenous fosfomycin (4 g four times a day for 10-14 days).
Follow-up
Follow-up occurred during hospitalization. Demographic, clinical and laboratory data were registered. Clinical outcomes were indeterminate (death, cessation of fosfomycin or additional use of another antimicrobial active in vitro against the microorganism during the first 72 h of treatment), therapeutic failure (death after 72 h of fosfomycin therapy, diagnosis of sepsis at end of treatment, introduction of another antimicrobial for treatment of Gram-negative infection or re-isolation of the agent 10 days after the antimicrobial treatment) and cure (absence of sepsis, attenuation or resolution of clinical signs and symptoms, improvement of support parameters defined by the attending team and improvement or normalization of tests related to therapeutic response). Mortality was evaluated at 14 and 28 days of treatment. We compared the group that received meropenem with the group that did not; the mean and standard deviation of APACHE II scores were calculated and compared using the t-test (Epiinfo v.7, CDC, Atlanta, GA, USA). Safety assessments included: gastrointestinal symptoms; rash; ototoxicity; nephrotoxicity; injection site pain; phlebitis; hypertension; heart failure; potassium, sodium, magnesium and chloride levels; neutropenia; eosinophilia; and changes in platelet counts and levels of transaminases.
Isolates
Identification and antimicrobial susceptibility testing were performed using automated Vitek MS and Vitek-2 systems (bioMérieux, Hazelwood, MO, USA). Resistance to carbapenems and colistin was confirmed by broth microdilution using CLSI breakpoints. 10 As there are no established colistin breakpoints for Enterobacteriaceae we used Acinetobacter cut-offs. 10 The MIC of fosfomycin was determined by agar dilution, adding glucose-6-phosphate. 10 Isolates from patients who received fosfomycin ! meropenem were investigated for synergism by chequerboard and time-kill assays. For chequerboard assays, synergism was defined as a fractional inhibitory concentration index 0.5.
11 For time-kill assays, fosfomycin and meropenem were tested alone and combined at 0.5 % MIC. Synergism was defined as a colony count at 24 h that was 2 log 10 lower with the combination than with the most active single agent and below the starting inoculum.
11
Clonality of Klebsiella pneumoniae isolates was investigated by PFGE using SpeI (Life Sciences, Canada), as previously described.
12 bla KPC , bla NDM , bla OXA-48 and mcr-1 genes were investigated using PCR. 13, 14 The isolates were also sequenced using MiSeq Illumina (Illumina, San Diego, CA, USA).
Results
There were 915 patients who met inclusion criteria; after application of the exclusion criteria 13 patients were admitted to the protocol. Eight (62%) were male. The mean age was 52 years (SD " 24). Underlying diseases were renal transplantation (n " 3), multiple trauma (n " 2), intestinal obstruction (n " 2), mesenteric thrombosis (n " 1), liver transplantation (n " 1), bone marrow aplasia (n " 1), Crohn's disease (n " 1), papillary tumour (n " 1) and CNS arteriovenous malformation (n " 1). Comorbidities were hypertension (n " 7), diabetes mellitus (n " 7), dyslipidaemia (n " 2), osteoarthritis (n " 1) and Chagas' disease (n " 1). Seven (54%) patients were immunosuppressed; 8 (62%) had undergone surgery within the previous 30 days. The mean APACHE II scores on admission and on the first day of treatment were 16 (SD " 7) and 16 (SD " 9), respectively. All patients had used antimicrobials previously: 12 (92%) had received a carbapenem, 7 (54%) colistin/ polymyxin B and 6 (46%) both of these. Four of 13 (31%) had had a previous infection and 9 (69%) were admitted to intensive care.
The mean number of hospital-days before isolation of the microorganism was 43 (SD " 49). Infections were central-lineassociated bloodstream infection (n " 6), bacteraemic abdominal infection (n " 3), bacteraemic ventilator-associated pneumonia (n " 1), ventilator-associated pneumonia (n " 1), bacteraemic urinary infection (n " 1) and surgical site infection (n " 1). Microorganisms were isolated from the blood (n " 11), tissue (n " 1) and tracheal aspirate (n " 1) and were K. pneumoniae (n " 9), Serratia marcescens (n " 3) and Pseudomonas aeruginosa (n " 1). Resistance to carbapenems and colistin was confirmed by broth microdilution (MIC .4 mg/L for meropenem and colistin). Fosfomycin MIC 50 and MIC 90 were 512 and 1024 mg/L, respectively. The most frequent carbapenemase was KPC, isolates had 6-10 polymorphisms in genes related to polymyxin resistance and most (91%) had the fosA gene. See Table 1 .
Three patients (23%) failed treatment, two (15%) had an indeterminate response and eight (62%) were cured. Fourteen and 28 day mortalities were 39% and 54%, respectively.
Meropenem was the most common antimicrobial used in combination with fosfomycin (n " 10), followed by amikacin (n " 3), tigecycline (n " 2), colistin (n " 2) and ertapenem (n " 1). Seven of 10 (70%) patients who received meropenem were cured, but only 1 of 3 who did not receive meropenem (33%), although APACHE II scores were similar [15.7+0.6 versus 16.5+7.9 (P " 0.85) and 15.3+3.8 versus 15.6+9.6 (P " 0.96), respectively].
Synergism between fosfomycin and meropenem occurred in all eight isolates tested by chequerboard. Time-kill assays showed synergism for the combination in 9 of 11 tested (82%) ( Table 1) .
K. pneumoniae were polyclonal, with three different pulsedfield types and three different STs ( Figure 1 ). P. aeruginosa belonged to ST245, not previously described in Brazil (Table 1) .
Eight (62%) patients had adverse events: hypokalaemia (n " 8), nausea (n " 3), vomiting (n " 2), diarrhoea (n " 2) and hypertension (n " 2; both had had prior episodes). Therapy was not discontinued owing to adverse events.
Discussion
Polymyxin-resistant infections have increased and alternative treatments are valuable. 1, 2 In vitro studies demonstrated fosfomycin activity, 3 which inspired us to study this drug in serious MDR infections.
Fosfomycin has already been used in critical patients, but more frequently in urinary infections. 3 Efficacy and safety studies using intravenous fosfomycin in critical patients are needed. Thirteen patients were included in a compassionate protocol and eight (62%) were cured of infection. Despite being from a small case series, we believe that this result was surprising given the severity of the patients' conditions. Many patient characteristics suggested a poor prognosis: most were 60 years old; most had comorbidities; Perdigão Neto et al. Efficacy and safety of fosfomycin JAC most had bacteraemic infections; severity scores were high; and seven were immunosuppressed. The high mortality reflects this. Fosfomycin MICs were high, which might have limited the success of monotherapy. There are only fosfomycin CLSI breakpoints for Escherichia coli and Enterococcus faecalis, and, extrapolating these to other microorganisms, nine (69%) isolates would be classified as resistant. Using EUCAST cutoffs, 15 10/13 were resistant. High MICs may be explained by the fosA gene being present in eight of nine isolates sequenced.
Meropenem MICs were also high. Most isolates carried KPC-2, which was expected owing to the high frequency of KPC-2 in Brazil. However, carbapenemase NDM-1 was found together with KPC-2 in one S. marcescens.
When fosfomycin and meropenem were combined, synergism occurred in most isolates. Some studies show synergism between meropenem and other antimicrobials, mostly colistin. 2 Reports on the combination of meropenem and fosfomycin are scarce. 16 Combination treatment of MDR Gram-negative bacteria is controversial. Some studies show benefit, 17 others not. 18 As fosfomycin and meropenem act at distinct stages of cell wall synthesis, we believe that the combination may overcome the expression of independent resistance mechanisms and lead to rupture of the cell wall and bacterial death, as previously suggested. 16 In general, fosfomycin is considered safe. 3 Episodic adverse events have been described with intravenous fosfomycin in lowdose retrospective studies, mostly gastrointestinal.
9 Serious events are rare, including leucopenia and neutropenia. 19 The high doses used in our study led to frequent adverse events, none severe.
Reports of treatment with intravenous fosfomycin are scarce. A retrospective study evaluated the efficacy of doripenem ! fosfomycin versus colistin ! fosfomycin in P. aeruginosa pneumonia; both were effective. 20 A study compared colistin with colistin ! fosfomycin against carbapenem-resistant Acinetobacter baumannii, but did not have adequate power to draw conclusions. 7 There is a report of fosfomycin in combination with several antimicrobials treating 116 patients with various infections. 6 Another study described 18 patients with primary bacteraemia receiving fosfomycin, with clinical success in 11. 8 The main limitation of our study is the small number of cases. However, fosfomycin was used against bacteria with different resistance mechanisms, species and clones, suggesting that it may be widely useful.
In conclusion, fosfomycin may be effective against infections caused by MDR Gram-negative microorganisms with different antimicrobial resistance mechanisms and there seems to be synergism with meropenem. Fosfomycin seems to be safe even in high doses.
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